GSK reported encouraging phase I BEHOLD-1 data for mocertatug rezetecan (Mo-Rez), an antibody-drug conjugate targeting the B7-H4 antigen. At the highest doses evaluated, Mo-Rez monotherapy achieved confir...
GSK reported encouraging phase I BEHOLD-1 data for mocertatug rezetecan (Mo-Rez), an antibody-drug conjugate targeting the B7-H4 antigen. At the highest doses evaluated, Mo-Rez monotherapy achieved confir...
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
